List view / Grid view
7 August 2013 | By Novartis
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."
5 August 2013 | By Sanofi
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide...
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
2 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide has been extended by three months...
1 August 2013 | By Boehringer Ingelheim
Data from the LUX-Lung clinical trial programme...
1 August 2013 | By Novartis
Novartis announced that the US FDA approved Menveo®...
31 July 2013 | By Sanofi
Sanofi announced the appointment of two new members to the Executive Committee, effective September 1st, 2013...
31 July 2013 | By AstraZeneca
Collaboration to include US, China and selected other markets...
31 July 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…
30 July 2013 | By kdm communications
LCTech GmbH has been using Tecan Cavro® components for many years...
30 July 2013 | By Abbott
Abbott announced promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay...
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
29 July 2013 | By Merck
Merck and the ADAP Crisis Task Force (ACTF) announced that the company will extend its commitment to support state AIDS Drug Assistance Programs (ADAPs)...
